SINOPHARM(CNCM LTD)(SH:600511) Shang Hai Zheng Quan Bao·2025-10-21 19:43Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药股份), has released its third-quarter report for 2025, ensuring the accuracy and completeness of the financial information presented [1][2][9]. Financial Data Summary - The financial statements for the third quarter of 2025 have not been audited [3]. - The report includes major accounting data and financial indicators, but specific figures are not detailed in the provided text [3]. - Non-recurring gains and losses are applicable, but the report does not specify any significant items [4]. - There are no changes reported in the major accounting data and financial indicators compared to the previous period [5]. Shareholder Information - The report does not provide details on the total number of shareholders or changes in the top ten shareholders [5]. Other Important Information - The board meeting for the approval of the third-quarter report was held on October 21, 2025, with all nine directors present, including four independent directors [8]. - The resolution to approve the third-quarter report was passed unanimously with nine votes in favor [9].